OTraces

OTraces is a biotechnology company that has developed a proprietary noise-suppression proteomics platform designed to enhance the sensitivity of cancer diagnostics. By utilizing its Chemical Diffusion Layer (CDL) technology, the company can detect low-abundance protein biomarkers that are often missed by conventional immunoassay methods. OTraces focuses on the early detection and monitoring of various cancers, including breast, prostate, and lung malignancies. Their diagnostic tests, such as BC-Sensa and PR-Sensa, aim to provide higher accuracy and reduce the rate of false results in clinical settings. The company's approach represents a shift toward physics-based signal enhancement in the field of liquid biopsy and proteomic analysis.